| Property | Value |
|---|
|
?:abstract
|
-
Soluble angiotensin converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV2, making native ACE2 on cell surfaces available to convert angiotensin-II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1152/ajpcell.00478.2020
|
|
?:journal
|
-
American_journal_of_physiology._Cell_physiology
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Soluble ACE2 as a potential therapy for COVID-19.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}